NO994295L - Nye screeningsmetoder for å identifisere midler som selektivt inhiberer hepatitt C-virusreplikasjon - Google Patents

Nye screeningsmetoder for å identifisere midler som selektivt inhiberer hepatitt C-virusreplikasjon

Info

Publication number
NO994295L
NO994295L NO994295A NO994295A NO994295L NO 994295 L NO994295 L NO 994295L NO 994295 A NO994295 A NO 994295A NO 994295 A NO994295 A NO 994295A NO 994295 L NO994295 L NO 994295L
Authority
NO
Norway
Prior art keywords
screening methods
virus replication
selectively inhibit
identify agents
new screening
Prior art date
Application number
NO994295A
Other languages
English (en)
Norwegian (no)
Other versions
NO994295D0 (no
Inventor
Michael G Katze
Jr Michael J Gale
Original Assignee
Ribogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribogene Inc filed Critical Ribogene Inc
Publication of NO994295D0 publication Critical patent/NO994295D0/no
Publication of NO994295L publication Critical patent/NO994295L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO994295A 1997-03-05 1999-09-03 Nye screeningsmetoder for å identifisere midler som selektivt inhiberer hepatitt C-virusreplikasjon NO994295L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3859697P 1997-03-05 1997-03-05
PCT/US1998/004226 WO1998039487A1 (en) 1997-03-05 1998-03-05 Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication

Publications (2)

Publication Number Publication Date
NO994295D0 NO994295D0 (no) 1999-09-03
NO994295L true NO994295L (no) 1999-11-02

Family

ID=21900807

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994295A NO994295L (no) 1997-03-05 1999-09-03 Nye screeningsmetoder for å identifisere midler som selektivt inhiberer hepatitt C-virusreplikasjon

Country Status (14)

Country Link
US (3) US6030785A (de)
EP (1) EP0975809A4 (de)
JP (1) JP2001514508A (de)
KR (1) KR20000075983A (de)
CN (1) CN1268980A (de)
AU (1) AU726374B2 (de)
CA (1) CA2283379A1 (de)
HU (1) HUP0001395A3 (de)
IL (1) IL131730A (de)
NO (1) NO994295L (de)
NZ (1) NZ337703A (de)
PL (1) PL335721A1 (de)
TR (1) TR199902561T2 (de)
WO (1) WO1998039487A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
JP2001508648A (ja) 1996-11-06 2001-07-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍壊死因子レセプター放出酵素、酵素を含む組成物、およびその使用方法
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
CA2283379A1 (en) * 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
WO2001053355A1 (en) * 2000-01-24 2001-07-26 The Trustees Of Columbia University In The City Of New York An in vivo screen using chemical inducers of dimerization
WO2001077394A1 (en) * 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001283547A1 (en) * 2000-08-09 2002-02-18 The Board Of Regents Of The University Of Nebraska Counter selection strategy for gram-negative bacteria
WO2002022880A1 (en) * 2000-09-13 2002-03-21 University Of Chicago Compositions and methods for the identification of viral inhibitors of host cell protein synthesis shut-off
US20020168737A1 (en) * 2001-01-24 2002-11-14 Cornish Virginia W. Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization
US6699657B2 (en) 2001-01-31 2004-03-02 Bristol-Myers Squibb Company In vitro system for replication of RNA-dependent RNA polymerase (RDRP) viruses
US7326536B2 (en) * 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
WO2003025209A1 (en) * 2001-09-21 2003-03-27 Ortho-Clinical Diagnostics, Inc. Use of hcv core antigen assay for screening of anti-viral compounds
EP1435974A4 (de) * 2001-09-28 2006-09-06 Idenix Cayman Ltd Verfahren und zusamemnsetzungen zur behandlung des hepatitis-c-virus mit 4'-modifizierten nucleosiden
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Ｈｃｖ 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
PT3025726T (pt) 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
US7083918B2 (en) * 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
WO2003095972A2 (en) * 2002-05-09 2003-11-20 The Regents Of The University Of California Method of analyzing ataxia-telangiectasia protein
US6690975B2 (en) * 2002-05-17 2004-02-10 Bistner Co., Ltd. Methods for treating hepatitis C
CA2488632A1 (en) * 2002-06-11 2003-12-18 Idaho Research Foundation Type i interferon-inducible proteins to detect viral infection
AU2003274897A1 (en) * 2002-07-10 2004-01-23 Stratagene California Humanized renilla reniformis green fluorescent protein as a scaffold
AU2003264038A1 (en) * 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
ES2294589T3 (es) * 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
DK2497492T3 (en) 2004-06-01 2018-11-26 Icahn School Med Mount Sinai Genetically modified swine influenza virus and its applications
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
WO2006019832A1 (en) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
PL1797112T3 (pl) * 2004-09-29 2011-04-29 The Administrators Of The Tulane Educational Fund Inhibitory wirusa zapalenia wątroby typu C
WO2006121468A1 (en) * 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
WO2006088481A2 (en) * 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
AR058419A1 (es) * 2005-02-28 2008-02-06 Gilead Sciences Inc Compuestos de nucleosidos triciclicos para tratar infecciones virales
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN101223161A (zh) * 2005-06-24 2008-07-16 健亚生物科技公司 治疗病毒感染的杂芳基衍生物
WO2007058384A1 (en) * 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
SG10201406016SA (en) * 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2007888A2 (de) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmazeutische zusammensetzung mit anti-mirna-antisense-oligonukleotiden
WO2008002165A2 (en) * 2006-06-30 2008-01-03 Krzysztof Kucharczyk A method, assay and kit for prediction and treatment of a human subject infected with a virus
BRPI0714299A2 (pt) * 2006-07-20 2013-04-24 Genelabs Tech Inc inibidores virais policÍclicos
KR100783287B1 (ko) * 2006-08-09 2007-12-06 한국생명공학연구원 텔로미어 전사 비활성화에 관여하는 화합물의 동정을 위한균주의 제조
CA2666191C (en) * 2006-10-09 2017-07-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US8470791B2 (en) * 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
JP2010537958A (ja) * 2007-08-30 2010-12-09 サンタリス ファーマ アー／エス Ｆａｂｐ４／ａｐ２を調節するためのｒｎａアンタゴニスト化合物
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
US20090162858A1 (en) * 2007-09-18 2009-06-25 Cornish Virginia W Orthogonal chemical inducer of dimerization
EP2623599B1 (de) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Mikromir-Moleküle
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
CN101314614B (zh) * 2008-06-16 2011-03-23 南开大学 与pkr激酶结构域特异性结合的多肽及其应用
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2456870A1 (de) 2009-07-21 2012-05-30 Santaris Pharma A/S Auf pcsk9 gerichtete antisense-oligomere
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
MA34462B1 (fr) 2010-07-22 2013-08-01 Novartis Ag Composes de thiophene 2,3,5- trisubstitues et leurs utilisations
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
WO2013103829A1 (en) * 2012-01-05 2013-07-11 Viracine Therapeutics Corporation Compositions and methods for screening antiviral agents
HUE048738T2 (hu) 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
WO2018195110A1 (en) * 2017-04-17 2018-10-25 University Of Florida Research Foundation, Incorporated Regolation of ran translation by pkr and eif2a-p pathways
EP3688020A4 (de) 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated Immunoassays zum nachweis von ran-proteinen
WO2021055880A1 (en) 2019-09-20 2021-03-25 University Of Florida Researchfoundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
DE69434931T2 (de) * 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
CA2283379A1 (en) 1997-03-05 1998-09-11 Michael G. Katze Novel screening methods to identify agents that selectively inhibit hepatitis c virus replication

Also Published As

Publication number Publication date
US7148006B2 (en) 2006-12-12
EP0975809A1 (de) 2000-02-02
PL335721A1 (en) 2000-05-08
EP0975809A4 (de) 2002-10-30
AU726374B2 (en) 2000-11-02
HUP0001395A1 (en) 2000-07-28
JP2001514508A (ja) 2001-09-11
KR20000075983A (ko) 2000-12-26
US6326151B1 (en) 2001-12-04
HUP0001395A3 (en) 2001-09-28
NO994295D0 (no) 1999-09-03
US20020155431A1 (en) 2002-10-24
US6030785A (en) 2000-02-29
TR199902561T2 (xx) 2000-02-21
CN1268980A (zh) 2000-10-04
IL131730A0 (en) 2001-03-19
WO1998039487A1 (en) 1998-09-11
CA2283379A1 (en) 1998-09-11
IL131730A (en) 2004-06-20
AU6684098A (en) 1998-09-22
NZ337703A (en) 2001-05-25

Similar Documents

Publication Publication Date Title
NO994295L (no) Nye screeningsmetoder for å identifisere midler som selektivt inhiberer hepatitt C-virusreplikasjon
ATE445372T1 (de) System zum inkrementellen bewegen von zähnen
DK125796A (da) I form af små molekyler foreliggende inhibitorer for rotamaseaktivitet
ID21649A (id) Inhibitor serum protease, terutama virus hepatitis c ns3 protease
ATE360506T1 (de) Werkzeug zum entfernen von einwegschrauben
DE69530012D1 (de) Festplatte
DE60139127D1 (de) Von hepatitis c virus
DK0802184T3 (da) N-Benzyl-2-phenylindoler som østrogene midler
ATE251612T1 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
ATE128181T1 (de) Tabletten zum reinigen von toiletten.
ATE215778T1 (de) Zusammensetzung zum abschrecken von schädlingen
DE69800779D1 (de) Photopolymerisierbare Zusammensetzung
DE69933094D1 (de) Photochrome polymerisierbare zusammensetzung
NO996520D0 (no) Opploeste sertralinblandinger
FI934777A7 (fi) Multipel hepatitis b virus ytproteiner som bildar partiklar
ATE224887T1 (de) Indolylderivate als serotonergische wirkstoffe
DE59904853D1 (de) Ethoxylierte esterquats
DE69730791D1 (de) Detektor eines Durchbruchereignisses
DE59807563D1 (de) Substituierte 2-(3-alkenyl-benzoyl)-cyclohexan-1,3-dione
ATE223380T1 (de) Heteroaryloxyethylaminen als 5-ht1a rezeptor liganden
KR960005219U (ko) 점탄성 교량 받침구
FR2760315B1 (fr) Andaineuse suspendue
ID20157A (id) Senyawa senyawa oligonukleotida spesifik untuk virus hepatitis b
DE69923861D1 (de) Il-5 hemmende 6-azauracilderivate
ES1024610Y (es) Rejilla para fondos de fregaderos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application